APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for HR+/HER2- Advanced Breast Cancer

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Drugs for HR+/HER2- Advanced Breast Cancer Industry Growth and Trends Forecast to 2032

22 December 202575 pages

Choose your research edition.

Industry ResearchDrugs for HR+/HER2- Advanced Breast Cancer Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for HR+/HER2- Advanced Breast Cancer Industry Growth and Trends Forecast to 203275 pages · $3,450 USDMarket StructureGlobal Drugs for HR+/HER2- Advanced Breast Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for HR+/HER2- Advanced Breast Cancer Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for HR+/HER2- Advanced Breast Cancer Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Drugs for HR+/HER2- Advanced Breast Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Drugs for HR+/HER2- Advanced Breast Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Drugs for HR+/HER2- Advanced Breast Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for HR+/HER2- Advanced Breast Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs for HR+/HER2- Advanced Breast Cancer include Eli Lilly and Company, Hengrui Pharma and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Drugs for HR+/HER2- Advanced Breast Cancer market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Drugs for HR+/HER2- Advanced Breast Cancer market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Drugs for HR+/HER2- Advanced Breast Cancer market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Drugs for HR+/HER2- Advanced Breast Cancer.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Drugs for HR+/HER2- Advanced Breast Cancer market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Drugs for HR+/HER2- Advanced Breast Cancer Market by Company

Eli Lilly and Company

Hengrui Pharma

Pfizer

Drugs for HR+/HER2- Advanced Breast Cancer Segment by Type

Abemaciclib

Dalpiciclib

Other

Drugs for HR+/HER2- Advanced Breast Cancer Segment by Application

Hospital

Retail Pharmacy

Other

Drugs for HR+/HER2- Advanced Breast Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for HR+/HER2- Advanced Breast Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for HR+/HER2- Advanced Breast Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for HR+/HER2- Advanced Breast Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for HR+/HER2- Advanced Breast Cancer manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Drugs for HR+/HER2- Advanced Breast Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Abemaciclib Table 2. Major Company of Dalpiciclib Table 3. Major Company of Other Table 4. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (k units) Table 6. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Type (2021-2026) Table 7. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (US$ Million) Table 8. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Type (2021-2026) Table 9. Global Drugs for HR+/HER2- Advanced Breast Cancer Price by Type (2021-2026) & (US$/unit) Table 10. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2027-2032) & (k units) Table 11. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Type (2027-2032) Table 12. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2027-2032) & (US$ Million) Table 13. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Type (2027-2032) Table 14. Global Drugs for HR+/HER2- Advanced Breast Cancer Price by Type (2027-2032) & (US$/unit) Table 15. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (k units) Table 16. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (k units) Table 18. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (k units) Table 20. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (k units) Table 22. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (k units) Table 24. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales by Type (2021-2026) & (US$ Million) Table 25. Drugs for HR+/HER2- Advanced Breast Cancer Industry Trends Table 26. Drugs for HR+/HER2- Advanced Breast Cancer Industry Drivers Table 27. Drugs for HR+/HER2- Advanced Breast Cancer Industry Opportunities and Challenges Table 28. Drugs for HR+/HER2- Advanced Breast Cancer Industry Restraints Table 29. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Drugs for HR+/HER2- Advanced Breast Cancer Revenue Market Share by Company (2021-2026) Table 31. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Company (2021-2026) & (k units) Table 32. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Share by Company (2021-2026) Table 33. Global Drugs for HR+/HER2- Advanced Breast Cancer Market Price by Company (2021-2026) & (US$/unit) Table 34. Global Drugs for HR+/HER2- Advanced Breast Cancer Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Drugs for HR+/HER2- Advanced Breast Cancer Major Company Production Sites and Headquarters Table 36. Global Drugs for HR+/HER2- Advanced Breast Cancer Company, Product Type & Application Table 37. Global Drugs for HR+/HER2- Advanced Breast Cancer Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Drugs for HR+/HER2- Advanced Breast Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Drugs for HR+/HER2- Advanced Breast Cancer Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Region (2021-2026) & (k units) Table 42. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Region (2021-2026) Table 43. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Region (2021-2026) & (US$ Million) Table 44. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Region (2021-2026) Table 45. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Region (2027-2032) & (k units) Table 47. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Region (2027-2032) Table 48. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Region (2027-2032) & (US$ Million) Table 49. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Region (2027-2032) Table 50. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 51. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (k units) Table 53. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Application (2021-2026) Table 54. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (US$ Million) Table 55. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Application (2021-2026) Table 56. Global Drugs for HR+/HER2- Advanced Breast Cancer Price by Application (2021-2026) & (US$/unit) Table 57. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2027-2032) & (k units) Table 58. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Application (2027-2032) Table 59. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2027-2032) & (US$ Million) Table 60. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Application (2027-2032) Table 61. Global Drugs for HR+/HER2- Advanced Breast Cancer Price by Application (2027-2032) & (US$/unit) Table 62. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (k units) Table 63. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (k units) Table 65. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (k units) Table 67. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (k units) Table 69. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (k units) Table 71. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales by Application (2021-2026) & (US$ Million) Table 72. Eli Lilly and Company Company Information Table 73. Eli Lilly and Company Business Overview Table 74. Eli Lilly and Company Drugs for HR+/HER2- Advanced Breast Cancer Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Eli Lilly and Company Drugs for HR+/HER2- Advanced Breast Cancer Product Portfolio Table 76. Eli Lilly and Company Recent Development Table 77. Hengrui Pharma Company Information Table 78. Hengrui Pharma Business Overview Table 79. Hengrui Pharma Drugs for HR+/HER2- Advanced Breast Cancer Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Hengrui Pharma Drugs for HR+/HER2- Advanced Breast Cancer Product Portfolio Table 81. Hengrui Pharma Recent Development Table 82. Pfizer Company Information Table 83. Pfizer Business Overview Table 84. Pfizer Drugs for HR+/HER2- Advanced Breast Cancer Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Pfizer Drugs for HR+/HER2- Advanced Breast Cancer Product Portfolio Table 86. Pfizer Recent Development Table 87. North America Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 88. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country (2021-2026) & (k units) Table 89. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share by Country (2021-2026) Table 90. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Forecast by Country (2027-2032) & (k units) Table 91. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share Forecast by Country (2027-2032) Table 92. North America Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 93. North America Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country (2021-2026) & (US$ Million) Table 94. North America Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Country (2021-2026) Table 95. North America Drugs for HR+/HER2- Advanced Breast Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 96. North America Drugs for HR+/HER2- Advanced Breast Cancer Market Share Forecast by Country (2027-2032) Table 97. Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 98. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country (2021-2026) & (k units) Table 99. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share by Country (2021-2026) Table 100. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Forecast by Country (2027-2032) & (k units) Table 101. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share Forecast by Country (2027-2032) Table 102. Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 103. Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country (2021-2026) & (US$ Million) Table 104. Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Country (2021-2026) Table 105. Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 106. Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Share Forecast by Country (2027-2032) Table 107. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 108. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country (2021-2026) & (k units) Table 109. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share by Country (2021-2026) Table 110. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Forecast by Country (2027-2032) & (k units) Table 111. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share Forecast by Country (2027-2032) Table 112. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 113. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country (2021-2026) & (US$ Million) Table 114. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Country (2021-2026) Table 115. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 116. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Share Forecast by Country (2027-2032) Table 117. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 118. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country (2021-2026) & (k units) Table 119. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share by Country (2021-2026) Table 120. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales Forecast by Country (2027-2032) & (k units) Table 121. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share Forecast by Country (2027-2032) Table 122. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country (2021-2026) & (US$ Million) Table 124. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Country (2021-2026) Table 125. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Market Share Forecast by Country (2027-2032) Table 127. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 128. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country (2021-2026) & (k units) Table 129. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share by Country (2021-2026) Table 130. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Forecast by Country (2027-2032) & (k units) Table 131. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share Forecast by Country (2027-2032) Table 132. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country (2021-2026) & (US$ Million) Table 134. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Country (2021-2026) Table 135. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Share Forecast by Country (2027-2032) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Drugs for HR+/HER2- Advanced Breast Cancer Distributors List Table 140. Drugs for HR+/HER2- Advanced Breast Cancer Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Drugs for HR+/HER2- Advanced Breast Cancer Image Figure 2. Global Drugs for HR+/HER2- Advanced Breast Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for HR+/HER2- Advanced Breast Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for HR+/HER2- Advanced Breast Cancer Sales (2021-2032) & (k units) Figure 5. Abemaciclib Image Figure 6. Global Abemaciclib Sales YoY Growth (2021-2032) & (k units) Figure 7. Dalpiciclib Image Figure 8. Global Dalpiciclib Sales YoY Growth (2021-2032) & (k units) Figure 9. Other Image Figure 10. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 11. Global Drugs for HR+/HER2- Advanced Breast Cancer Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Type 2025 VS 2032 Figure 13. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Type in 2025 Figure 14. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Type in 2025 Figure 15. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Type in 2025 Figure 16. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Type in 2025 Figure 19. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Drugs for HR+/HER2- Advanced Breast Cancer Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Image Figure 26. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 27. Retail Pharmacy Image Figure 28. Global Retail Pharmacy Sales YoY Growth (2021-2032) & (k units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 31. Global Drugs for HR+/HER2- Advanced Breast Cancer Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Application 2025 VS 2032 Figure 33. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Application in 2025 Figure 34. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Application in 2025 Figure 35. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Application in 2025 Figure 36. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Application in 2025 Figure 39. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Market Share in Value by Application in 2025 Figure 43. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Drugs for HR+/HER2- Advanced Breast Cancer Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Drugs for HR+/HER2- Advanced Breast Cancer Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Abemaciclib
  • Dalpiciclib
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Eli Lilly and Company
  • Hengrui Pharma
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for HR+/HER2- Advanced Breast Cancer Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Drugs for HR+/HER2- Advanced Breast Cancer Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Drugs for HR+/HER2- Advanced Breast Cancer Market by Type
  6. 1.3.1 Abemaciclib
  7. 1.3.2 Dalpiciclib
  8. 1.3.3 Other
  9. 1.4 Global Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Type
  10. 1.4.1 Global Drugs for HR+/HER2- Advanced Breast Cancer Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Drugs for HR+/HER2- Advanced Breast Cancer Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Drugs for HR+/HER2- Advanced Breast Cancer Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Drugs for HR+/HER2- Advanced Breast Cancer Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Drugs for HR+/HER2- Advanced Breast Cancer Industry Trends
  2. 2.2 Drugs for HR+/HER2- Advanced Breast Cancer Industry Drivers
  3. 2.3 Drugs for HR+/HER2- Advanced Breast Cancer Industry Opportunities and Challenges
  4. 2.4 Drugs for HR+/HER2- Advanced Breast Cancer Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Drugs for HR+/HER2- Advanced Breast Cancer Revenue (2021-2026)
  2. 3.2 Global Top Players by Drugs for HR+/HER2- Advanced Breast Cancer Sales (2021-2026)
  3. 3.3 Global Top Players by Drugs for HR+/HER2- Advanced Breast Cancer Price (2021-2026)
  4. 3.4 Global Drugs for HR+/HER2- Advanced Breast Cancer Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for HR+/HER2- Advanced Breast Cancer Major Company Production Sites & Headquarters
  6. 3.6 Global Drugs for HR+/HER2- Advanced Breast Cancer Company, Product Type & Application
  7. 3.7 Global Drugs for HR+/HER2- Advanced Breast Cancer Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for HR+/HER2- Advanced Breast Cancer Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for HR+/HER2- Advanced Breast Cancer Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for HR+/HER2- Advanced Breast Cancer Tier 1, Tier 2, and Tier 3
4 Drugs for HR+/HER2- Advanced Breast Cancer Regional Status and Outlook
  1. 4.1 Global Drugs for HR+/HER2- Advanced Breast Cancer Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Drugs for HR+/HER2- Advanced Breast Cancer Historic Market Size by Region
  3. 4.2.1 Global Drugs for HR+/HER2- Advanced Breast Cancer Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Drugs for HR+/HER2- Advanced Breast Cancer Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Drugs for HR+/HER2- Advanced Breast Cancer Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Drugs for HR+/HER2- Advanced Breast Cancer Forecasted Market Size by Region
  7. 4.3.1 Global Drugs for HR+/HER2- Advanced Breast Cancer Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Drugs for HR+/HER2- Advanced Breast Cancer Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Drugs for HR+/HER2- Advanced Breast Cancer Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Drugs for HR+/HER2- Advanced Breast Cancer by Application
  1. 5.1 Drugs for HR+/HER2- Advanced Breast Cancer Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Application
  6. 5.2.1 Global Drugs for HR+/HER2- Advanced Breast Cancer Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Drugs for HR+/HER2- Advanced Breast Cancer Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Drugs for HR+/HER2- Advanced Breast Cancer Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Drugs for HR+/HER2- Advanced Breast Cancer Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Eli Lilly and Company
  2. 6.1.1 Eli Lilly and Company Company Information
  3. 6.1.2 Eli Lilly and Company Business Overview
  4. 6.1.3 Eli Lilly and Company Drugs for HR+/HER2- Advanced Breast Cancer Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Eli Lilly and Company Drugs for HR+/HER2- Advanced Breast Cancer Product Portfolio
  6. 6.1.5 Eli Lilly and Company Recent Developments
  7. 6.2 Hengrui Pharma
  8. 6.2.1 Hengrui Pharma Company Information
  9. 6.2.2 Hengrui Pharma Business Overview
  10. 6.2.3 Hengrui Pharma Drugs for HR+/HER2- Advanced Breast Cancer Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Hengrui Pharma Drugs for HR+/HER2- Advanced Breast Cancer Product Portfolio
  12. 6.2.5 Hengrui Pharma Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Drugs for HR+/HER2- Advanced Breast Cancer Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Drugs for HR+/HER2- Advanced Breast Cancer Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
7 North America by Country
  1. 7.1 North America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country
  2. 7.1.1 North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country (2021-2026)
  4. 7.1.3 North America Drugs for HR+/HER2- Advanced Breast Cancer Sales Forecast by Country (2027-2032)
  5. 7.2 North America Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country
  6. 7.2.1 North America Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country (2021-2026)
  8. 7.2.3 North America Drugs for HR+/HER2- Advanced Breast Cancer Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country
  2. 8.1.1 Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country (2021-2026)
  4. 8.1.3 Europe Drugs for HR+/HER2- Advanced Breast Cancer Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country
  6. 8.2.1 Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country (2021-2026)
  8. 8.2.3 Europe Drugs for HR+/HER2- Advanced Breast Cancer Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country
  2. 9.1.1 Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country
  6. 9.2.1 Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Drugs for HR+/HER2- Advanced Breast Cancer Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country
  2. 10.1.1 South America Drugs for HR+/HER2- Advanced Breast Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country (2021-2026)
  4. 10.1.3 South America Drugs for HR+/HER2- Advanced Breast Cancer Sales Forecast by Country (2027-2032)
  5. 10.2 South America Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country
  6. 10.2.1 South America Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country (2021-2026)
  8. 10.2.3 South America Drugs for HR+/HER2- Advanced Breast Cancer Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country
  2. 11.1.1 Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country
  6. 11.2.1 Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Drugs for HR+/HER2- Advanced Breast Cancer Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Drugs for HR+/HER2- Advanced Breast Cancer Value Chain Analysis
  2. 12.1.1 Drugs for HR+/HER2- Advanced Breast Cancer Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Drugs for HR+/HER2- Advanced Breast Cancer Production Mode & Process
  7. 12.2 Drugs for HR+/HER2- Advanced Breast Cancer Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Drugs for HR+/HER2- Advanced Breast Cancer Distributors
  10. 12.2.3 Drugs for HR+/HER2- Advanced Breast Cancer Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst